Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:24 AM
Ignite Modification Date:
2025-12-25 @ 12:24 AM
NCT ID:
NCT03127358
Eligibility Criteria:
Inclusion Criteria:
* HCV-infected (HCV RNA test above the limit of quantification at baseline)
* Genotypes/Subtypes: G1a or G1b
* Eligible for HCV treatment per 2016 AASLD/IDSA guidelines
* Willing to receive HCV treatment on-site at DoSA clinics
* Health care provider decision to treat patient with Zepatier-based therapy with or without ribavirin based on 2016 AASLD/IDSA guidelines
* Using illicit drugs (either opiates, cocaine, or benzodizepenes) within the last 6 months
* Age 18 or older
* Able to provide informed consent
* English or Spanish speaking
Exclusion Criteria:
* Known hypersensitivity (allergy) to elbasvir, grazoprevir, or ribavirin
* Pregnant or breast-feeding
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03127358
Study Brief:
Protocol Section:
NCT03127358